Artiva Biotherapeutics is cutting about 94% of its workforce and abandoning AlloNK, the immunotherapy it had pinned to a planned Phase 3 trial, after updated data showed the treatment’s benefit did not last long enough to justify further development. The move effectively ends the company’s only program and leaves it weighing what comes next.
The decision landed on Tuesday, when investors and employees got the clearest sign yet that the company’s path had narrowed sharply. Artiva said the data showed AlloNK was initially effective in clinical trials, but longer-term results failed to meet the threshold the company required to keep going.
That matters now because Artiva had 115 full-time employees in June and had been planning to grow, according to federal filings, making the layoffs a dramatic reversal rather than a routine reset. The company, founded in 2019, had also raised roughly $300 million from investors about five months before the cut, giving it a cash cushion that still did not change the outcome for its lead drug candidate.
The company’s leader, Fred Aslan, said he was deeply saddened by the deaths of two patients in the clinical studies and extended condolences to their families. One Phase 2a participant suffered a fatal neurological event, leukoencephalopathy, and an investigator determined that death was likely related to fludarabine. A second participant died suddenly about two months after starting treatment; that death was ruled unrelated to AlloNK or any other part of the study regimen, although the exact cause remains undetermined.
Artiva said AlloNK was an off-the-shelf natural killer cell therapy for rheumatoid arthritis and that the therapy’s durability did not clear the bar it had set for continued development. The company said it was spending $11.8 million on drug development and $10.8 million on personnel last year, with staffing and clinical work its biggest costs.
By Sept. 30, Artiva held about $319.1 million in cash and investments, but the company said it is now exploring alternatives that maximize shareholder value. Noopur Batsha Liffick said there is no specific timeline and confirmed that, with AlloNK gone, Artiva is looking at whether a sale, merger or liquidation makes the most sense.
The question now is not whether AlloNK survives. It does not. The more immediate question is which exit Artiva chooses first, and how much of the company is left to carry it there.
